Production (Stage)
Akero Therapeutics, Inc.
AKRO
$46.36
-$2.61-5.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 21.61% | 2.96% | 18.67% | 36.30% | 33.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.91% | 26.11% | 75.27% | 84.52% | 108.51% |
| Operating Income | -34.91% | -26.11% | -75.27% | -84.52% | -108.51% |
| Income Before Tax | -32.58% | -26.89% | -83.33% | -80.12% | -106.51% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -32.58% | -26.89% | -83.33% | -80.12% | -106.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -32.58% | -26.89% | -83.33% | -80.12% | -106.51% |
| EBIT | -34.91% | -26.11% | -75.27% | -84.52% | -108.51% |
| EBITDA | -34.90% | -26.08% | -75.29% | -84.57% | -108.59% |
| EPS Basic | 0.02% | -0.17% | -46.82% | -35.07% | -63.44% |
| Normalized Basic EPS | 0.04% | 4.02% | -46.83% | -35.11% | -63.48% |
| EPS Diluted | 0.02% | -0.17% | -46.82% | -35.00% | -63.44% |
| Normalized Diluted EPS | 0.04% | 4.02% | -46.83% | -35.11% | -63.48% |
| Average Basic Shares Outstanding | 32.62% | 26.66% | 24.87% | 33.34% | 26.34% |
| Average Diluted Shares Outstanding | 32.62% | 26.66% | 24.87% | 33.34% | 26.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |